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Abstract Purpose: Soluble Trig-
gering Receptor Expressed on
Myeloid cells-1 (sTREM-1) has pro-
ven to be a good biomarker for sepsis.
For the diagnosis ventilator-associ-
ated pneumonia (VAP), however,
there have only been a few, relatively
small, studies on the role of this
receptor. The aim of the study was to
evaluate the usefulness of sTREM-1
in bronchoalveolar lavage ﬂuid
(BALF) from Intensive Care Unit
patients as rapid diagnostic test for
VAP. Methods: The concentration
of sTREM-1 in 240 BALF samples
was measured using a quantitative
sandwich enzyme immunoassay. Two
researchers who were blind to the
assay results determined whether a
VAP was present or not. Clinical
suspicion of a VAP was conﬁrmed by
the presence of C2% cells containing
intracellular organisms and/or a
quantitative culture result of C10
4
colony forming units per millilitre
BALF. Results: The mean concen-
tration of sTREM-1 was signiﬁcantly
higher in the BALF of patients with
conﬁrmed VAP than in that of
patients without conﬁrmed VAP.
However, the area under the receiver-
operating characteristic curve was
0.58 (95% conﬁdence interval 0.50–
0.65, P = 0.04). Conclusions: The
results imply that the sTREM-1 assay
in BALF may not be discriminative
for VAP.
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Introduction
The diagnosis of ventilator-associated pneumonia (VAP),
a complication that often arises in patients receiving
mechanical ventilation, is difﬁcult. Clinical suspicion
alone is not reliable [1] and may lead to an overestimation
of VAP, resulting in unnecessary antibiotic therapy.
Results from invasive procedures, such as quantitative
culture of bronchoalveolar lavage ﬂuid (BALF), have
proven to be useful [2], but these are not available for
24–48 h. A potential candidate as a rapid diagnostic test
for VAP is soluble Triggering Receptor Expressed on
Myeloid cells-1 (sTREM-1). Testing for sTREM-1 in
BALF has promising results with a sensitivity of 98% and
a speciﬁcity of 90% [3].
TREM-1 is shed from membranes of activated
phagocytes and is found in soluble form in body ﬂuids.
It is a glycoprotein, expressed as receptor on neutro-
phils and CD14
high monocytes/macrophages [4]. The
expression of TREM-1 is strongly up-regulated in
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In humans, sTREM-1 in the blood proved to be a good
biomarker for sepsis [6]. For pneumonia, however, the
value of sTREM-1 in BALF [3, 7–10] has received
varying assessments. To evaluate the usefulness of
sTREM-1 as rapid diagnostic test for VAP, we tested
240 BALF samples from intensive care unit (ICU)
patients.
Materials and methods
Patients
This is a retrospective study that included patients
admitted to the ICU of Maastricht University Medical
Centre, who underwent BAL while receiving mechanical
ventilation. In all patients, mechanical ventilation was
initiated on the day of admission. Patients were screened
daily for VAP using clinical criteria, and BAL was per-
formed on the day of clinical suspicion. For each patient
receiving more than one BAL, the BALs were included in
the study when the time period between BALs was
C2 weeks; when there was \2 weeks between BALs,
only the ﬁrst BAL was included.
Baseline criteria were recorded (Table 1). Time
between ICU admission and BAL was also determined.
Study protocols were approved by the institutional review
board for human studies. Informed consent regarding the
use of data for research purposes was obtained from
patients or their legal representatives.
VAP diagnosis
Clinical suspicion of VAP was according to the deﬁnition
of Bonten et al. [11], and VAP was considered to be
acquired upon manifestation of the disease after C48 h of
mechanical ventilation. Clinically suspected VAP was
considered conﬁrmed VAP when the microbiological
results met the following criteria [11, 12]: presence of
C2% cells containing intracellular organisms (ICO) and/
or quantitative culture result of C10
4 colony forming
units (cfu) per millilitre of BALF.
Following BAL, antibiotic therapy was started
empirically in patients who had not previously received
treatment. When patients developed a VAP while
receiving antibiotics, the therapy was adjusted. Antibiotic
treatment before and during BAL does not inﬂuence the
predictive value of the percentage ICO in BALF in
diagnosing VAP [12]. Thus, due to the combination of
quantitative BALF culture and presence of ICO, adjust-
ment of the cfu/ml threshold was unnecessary to diagnose
VAP correctly when antibiotics were being used before
the BAL.
Two researchers (Guy J. Oudhuis and A. Verbon) retro-
spectively determined whether patients met the criteria of
clinically suspected and conﬁrmed VAP, independently
from one another and blind to the sTREM-1 assay results.
Thisyieldedtwostudygroups;aconﬁrmedVAPgroupanda
group in which VAP could not be conﬁrmed. A consensus
diagnosis was achieved in all cases.
Bronchoalveolar lavage
Bronchoscopy with directed BAL was performed as
described previously [12]. Samples were processed within
1 h after the BAL. All aliquots were pooled, except for the
ﬁrst one. The BALF samples were Gram-stained, and
quantitative culture was performed as described previ-
ously [13]. The urea concentration was determined by
means of an enzymatic conductivity rate method using the
SYNCHRON LX System (Beckman Coulter BV, Mijdr-
echt, The Netherlands) as previously described [14]. The
remaining BALF was centrifuged at 250 g for 10 min.
The supernatant was stored at –80C in six different ali-
quots until further processing.
Soluble Triggering Receptor Expressed on Myeloid
cells-1 assay
A quantitative sandwich enzyme immunoassay (Quanti-
kine Human TREM-1 Immunoassay; R&D Systems,
Minneapolis, MN), was used to detect sTREM-1 in BALF
in accordance to the manufacturers’ instructions, as
described previously [7].
The measured concentration of sTREM-1 in BALF
samples is not identical to that in the epithelial lining ﬂuid
(ELF), secondary to dilution of the BALF. To calculate
the concentration sTREM-1 in ELF from the concentra-
tion of sTREM-1 in BALF, we applied a correction with a
dilution factor using the ratio of urea concentration in the
serum and BALF [15].
Statistical analysis
The Mann–Whitney U test was used for the numerical
data; for sTREM-1 concentrations, we used Student’s t
test to compare logarithmic means. The Pearson v
2 test
was used for categorical data. The analyses were cor-
rected, by clustered logistic regression, for the inﬂuence
of multiple BALs performed in the same patient. To
evaluate the diagnostic value of the sTREM-1 assay, we
produced a receiver-operating characteristic (ROC) curve
and measured the area under the curve. Statistical sig-
niﬁcance was deﬁned as a P value of\0.05 in all cases.
Analysis was performed with SPSS ver. 14.0 for Win-
dows (SPSS, Chicago, IL).
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Patients
Between January 2001 and October 2006, 361 BALs were
performed, of which 59 were excluded from our retro-
spective analysis since they did not meet the quality
criteria [12], and 62 were excluded because they were
performed within 48 h after ICU admission. The
remaining 240 BALs, performed in 207 patients were
included in our study.
Seven patients underwent three BALs, 19 patients
underwent two BALs and 181 patients had one BAL. The
presence of VAP was conﬁrmed in 97 cases (40.4%) and
not conﬁrmed in 143 cases (59.6%).
Conﬁrmed VAP cases did not differ signiﬁcantly from
unconﬁrmed cases, and both groups did not differ sig-
niﬁcantly in terms of in-hospital mortality and ICU
mortality (Table 1). The number of patients with chronic
obstructive pulmonary disease (COPD) was low and did
not differ between both study groups (Table 1).
Soluble Triggering Receptor Expressed on Myeloid
cells-1 levels
The mean sTREM-1 concentration was signiﬁcantly
higher in the BALF of patients with conﬁrmed VAP [1849
pg/ml, 95% conﬁdence interval (CI) 1515–2256 pg/ml]
Table 1 Characteristics of the study population
Characteristic All
patients
a
(n = 207)
Patients with
conﬁrmed VAP
(n = 90)
Patients without
conﬁrmed VAP
(n = 117)
P value
(two groups
compared)
Sex
Male (%) 130 (62.8) 54 (60) 76 (65) 0.46
Female (%) 77 (37.2) 36 (40) 41 (35)
Age, years, median
(interquartile range)
62 (47–72) 65.50 (47–73.25) 61 (47.50–71) 0.43
Days in hospital
Mean (± SEM) 68.0 (4.6) 75.7 (9.0) 62.1 (4.2) 0.76
Range 6–540 6–540 8–322
Days in ICU
Mean (± SEM) 39.8 (2.8) 45.1 (5.7) 35.8 (2.3) 0.77
Range 6–397 6–397 7–168
Days in ICU before BAL
b
Mean (± SEM) 15.5 (0.9) 15.3 (1.5) 15.7 (1.2) 0.63
Range 2–83 3–83 2–73
APACHE II score
c
Mean (± SEM) 23 (0.5) 23 (0.9) 23 (0.6) 0.83
Range 4–44 4–44 7–40
Mortality in ICU (%) 72 (34.8) 33 (36.7) 39 (33.3) 0.62
Mortality in hospital (%) 83 (40.1) 41 (45.6) 42 (35.9) 0.16
History of COPD (%) 10 (4.8) 5 (5.6) 5 (4.3) 0.67
Medical specialty (%)
Medical 71 (34.3) 24 (26.7) 47 (40.2)
0.26
Surgical 78 (37.7) 35 (38.9) 43 (36.8)
Trauma 34 (16.4) 19 (21.1) 15 (12.8)
Neurological 18 (8.7) 9 (10.0) 9 (7.7)
Other
d 6 (2.9) 3 (3.3) 3 (2.6)
Reason for ICU admission (%)
Respiratory insufﬁciency 25 (12.1) 10 (11.1) 15 (12.8)
0.21
Trauma 28 (13.5) 15 (16.7) 13 (11.1)
Shock 52 (25.1) 19 (21.1) 33 (28.2)
Cardiopulmonary failure 17 (8.2) 4 (4.4) 13 (11.1)
Pneumonia 32 (15.5) 13 (14.4) 19 (16.2)
Neurological disease 15 (7.2) 7 (7.8) 8 (6.8)
Post-operative 38 (18.4) 22 (24.4) 16 (13.7)
VAP, Ventilator-associated pneumonia; BAL, bronchoalveolar
lavage; SEM, standard error of the mean; ICU, intensive care unit;
COPD, chronic obstructive pulmonary disease; APACHE II, Acute
Physiology and Chronic Health Evaluation II
a Seven patients underwent three BALs, 19 patients two BALs and
181 patients had one BAL. None of these patients had more than
one positive BAL within a time period of 14 days
b All 240 BALs are included in this item
c 10% of the APACHE II scores could not be retrospectively cal-
culated. The patients involved did not differ from the other patients
in this study
d Including otorhinolaryngology, paediatrics, gynaecology and oral
surgery
1267than in those without conﬁrmed VAP (1424 pg/ml, 95%
CI 1218–1664 pg/ml; P = 0.04; Fig. 1a).
Mean sTREM-1 levels did not differ between patients
with COPD (1570 pg/ml, 95% CI 1081–2279 pg/ml) and
those without (1617 pg/ml, 95% CI 1404–1863 pg/ml)
(P = 0.93).
No signiﬁcant difference in mean sTREM-1 level was
observed between medical patients (1676 pg/ml, 95% CI
1352–2077 pg/ml) and surgical patients (2233 pg/ml, 95%
CI 1769–2817 pg/ml) (P = 0.08), while the number of
conﬁrmed VAP cases did not differ between both groups
(P = 0.17).
Diagnostic value of sTREM-1
A ROC curve analysis showed an area under the curve of
0.58 (95% CI 0.50–0.65; P = 0.04; Fig. 1b). Therefore,
the sTREM-1 levels in our hands were not discriminative
for VAP. Choosing a sensitivity of 95% resulted in a
positive predictive value (PPV) of 41% and a negative
predictive value (NPV) of 62% in our population. A
speciﬁcity of 95% led to a PPV of 67% and a NPV of 62%.
Discussion
In this study, sTREM-1 levels were not discriminative for
VAP. The differences between the results of our study
and those of ﬁve other trials in terms of sTREM-1 and
pneumonia are highlighted in Table 2. These may explain
the differences in results. A correction for the dilution of
BAL has been found to allow a better representation of
the actual concentration of sTREM-1 in the alveoli [15].
However, this does not appear to explain the major dif-
ferences in outcome, since using the concentration of
sTREM-1 without correction for dilution did not result in
a signiﬁcantly better ROC analysis in our study (data not
shown).
Samples from medical and surgical patients were
included in this study. Our results show that the sTREM-1
levels tended to be higher in surgical patients, which is in
accordance with the results of other studies in which
surgery was reported to increase sTREM-1 expression
levels in peripheral blood monocytes independent of
infection [16]. We therefore conclude that in terms of
diagnosing VAP in an every day ICU setting, the mea-
surement of sTREM-1 levels in BALF does not seem to
be discriminative for VAP.
The levels of sTREM-1 are not only increased by
infecting micro-organisms [17]; cancer cells have also
been shown to be able to directly up-regulate TREM-1
expression in patients’ macrophages [18]. A number of
inﬂammatory disorders, such as pancreatitis, are also
known to increase levels of sTREM-1 [19]. In contrast,
TREM-1 is not up-regulated in samples from patients with
other inﬂammatory disorders, such as psoriasis, ulcerative
colitis or vasculitis caused by immune complexes [5].
The strength of this study is that it was performed in a
large, well-deﬁned group of both medical and surgical
ICU patients. One limitation may be that the analysis was
performed retrospectively. Only patients that underwent
BAL C48 h after being admitted to the ICU were inclu-
ded in the study. Therefore, these patients stayed longer in
a ICU than the general ICU population. A second limi-
tation may be that VAP is still difﬁcult to diagnose.
However, we used the widely accepted modiﬁed criteria
of the Centers for Disease Control [11] to diagnose VAP
and conﬁrmed the diagnosis by both staining for ICO and
culturing BALF samples [12].
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Fig. 1 a Mean soluble Triggering Receptor Expressed on Myeloid
cells-1 (sTREM-1) levels in bronchoalveolar lavage ﬂuid (BALF)
samples of conﬁrmed (n = 97) and non-conﬁrmed ventilator-
associated pneumonia (VAP)( n = 143) cases. Vertical bars 95%
conﬁdence intervals of the mean. b Receiver-operating character-
istic (ROC) curve analysis of sTREM-1 in BALF samples of
patients with and without conﬁrmed VAP
1268Conclusion
In conclusion, the results of this study imply that the
sTREM-1 assay on BALF samples as a rapid diagnostic
test for VAP may not be discriminative.
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